Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate that 300 mg secukinumab administered every 2 weeks is superior in achieving PASI 90 at week 32 compared to 300 mg secukinumab every 4 weeks in patients who after treatment with the standard dose had less than almost clear skin (PASI≥75 to PASI<90) at week 16.
Critère d'inclusion
- chronic moderate to severe plaque type psoriasis